US court invalidates one of two Gemzar patents
19 August 2009
Nancy Faigen
Please Login to read the full article.
19 August 2009
Nancy Faigen
nancy.faigen@informausa.com
A US district court has granted a motion filed by
Sun Pharma for partial summary judgement in its three-year battle over
Lilly's Gemzar (gemcitabine HCl for injection) – invalidating Lilly's method-of-use patent (the '826 patent), which includes paediatric exclusivity and is set to expire...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US court order blocks Cymbalta generics until patent ends in June 2013
- Mylan loses bid to have US Teva patent infringement suit on Copaxone tossed out
- Metaphors of rocks and baseball bats dominate arguments in Myriad patent case
- Pfizer's 'non obvious' Viagra patents good until 2019 to fend off Teva in US
COMMENT
Other Informa Comment
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
